PDS Biotechnology Corporation develops immunotherapies aimed at treating various cancers and infectious diseases. The company utilizes its proprietary Versamune® platform to enhance T cell responses against tumors, focusing on conditions such as head and neck cancer, cervical cancer, prostate cancer, and breast cancer. PDS Biotech operates primarily in the biotechnology sector, targeting healthcare providers and patients in need of advanced cancer treatments. Its research and development efforts are concentrated in the United States.
